Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 5/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25489077 | 0.87 | L3MBTL1 (0.38) | L3MBTL1METALPLRAB9ATDP1 | |
| SCHEMBL24038901 | 0.84 | MET (0.48) | L3MBTL1METHDAC1RAB9ATSHR | |
| SCHEMBL25487843 | 0.84 | MET (0.41) | L3MBTL1METALPLHDAC1RAB9A | |
| SCHEMBL25489127 | 0.79 | MET (0.41) | METHDAC1RAB9AKDM4EGAA | |
| SCHEMBL25484936 | 0.78 | MET (0.48) | METHDAC1TSHRTP53 | |
| SCHEMBL25489125 | 0.77 | TP53 (0.44) | METHDAC1KDM4EGAAMEN1 | |
| SCHEMBL25485108 | 0.76 | AKR1B1 (0.45) | METHDAC1KDM4EGAATSHR | |
| SCHEMBL31150642 | 0.76 | AKR1B1 (0.45) | METHDAC1KDM4EGAATSHR | |
| SCHEMBL24039001 | 0.76 | KDM4E (0.49) | HDAC1TDP1KDM4EGAATSHR | |
| SCHEMBL25485146 | 0.76 | MET (0.44) | METHDAC1KDM4EGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336609-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2023091606-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336609-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | L3MBTL1 4133/4885MET 4212/4885ALPL 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.